Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication

Clinical Therapeutics

Volumn 37, Issue 1, 2015, Pages 114-123.e1

  Hartung, Daniel M ^a   Middleton, Luke ^a   Markwardt, Sheila ^a   Williamson, Kaylee ^a   Ketchum, Kathy ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adrenergic 2 agonists; Medicaid; US Food and Drug Administration; Utilization

Indexed keywords

ARFORMOTEROL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; PROPIONIC ACID; SALMETEROL; SALMETEROL XINAFOATE; BRONCHODILATING AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ADVISORY COMMITTEE; ARTICLE; ASTHMA; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INHALATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL HISTORY; MONOTHERAPY; PRESCRIPTION; PROGRAM APPROPRIATENESS; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TREATMENT DURATION; ADOLESCENT; CHILD; CLINICAL PRACTICE; PATIENT SAFETY; PRACTICE GUIDELINE; TRENDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; BRONCHODILATOR AGENTS; CHILD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PATIENT SAFETY; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84920770524     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.10.025     Document Type: Article

References (37)

1. Chan CM, Shorr AF. Black clouds and black boxes: comment on "Long-acting beta2-agonist step-off in patients with controlled asthma". Arch Intern Med. 2012;172:1375-1376.
2. Aaronson DW. The "black box" warning and allergy drugs. Allergy Clin Immunol. 2006;117:40-44.
3. Castle W, Fuller R, Hall J, Palmer J. Serevent Nationwide Surveillance Study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034-1037.
4. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
5. Briefing Information for the March 10-11, 2010 Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Committee. US Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/Pulmonary-Allergy DrugsAdvisoryCommittee/UCM202 698.pdf (Accessed November 17, 2014).
6. Sears MR. The FDA-mandated trial of safety of long-acting beta-agonists in asthma: finality or futility? Thorax. 2013;68:195-198.
7. IMS. Top-Line Market Data. http:// www.imshealth.com/portal/site/ims/ menuitem.5ad1c081663fdf9b41d84 b903208c22a/?vgnextoid=fbc65890d33ee210VgnVCM10000071812ca2 RCRD.
8. Wasilevich EA, Clark SJ, Cohn LM, Dombkowski KJ. Long-acting betaagonist monotherapy among children and adults with asthma. Am J Manag Care. 2011;17:e91-e95.
9. 2- adrenergic agonists utilization in asthma patients. J Asthma. 2012; 49:1079-1085.
10. Friedman H, Wilcox T, Reardon G, et al. A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population. Clin Ther. 2008; 30:1908-1917.
11. Friedman HS, Eid NS, Crespi S, et al. Retrospective claims study of fluticasone propionate/salmeterol fixeddose combination use as initial asthma controller therapy in children despite guideline recommendations. Clin Ther. 2009;31:1056-1063.
12. Stockl KM, Le L, Harada AS, Zhang S. Use of controller medications in patients initiated on a long-acting beta2-adrenergic agonist before and after safety alerts. Am J Health Syst Pharm. 2008;65:1533-1538.
13. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma-full report 2007; 2007.
14. Drug Use Evaluation: LongActing Beta Agonist (LABA). Oregon State University College of Pharmacy - Drug Use Research and Management, 2006. http://pharmacy.ore gonstate.edu/drug-policy/sites/de fault/fi les/pages/dur-board/evaluations/articles/laba.pdf.
15. Combination Long-Acting Beta-Agonist Inhaled Corticosteroid: Summary of Clinical Evidence and Drug Utilization Evaluation. 2010. http:// pharmacy.oregonstate.edu/drug-po licy/sites/default/ fi les/pages/dur- board/evaluations/articles/laba-ics- due.pdf. Accessed September 1, 2013.
16. Helm ME, Vargas PA, Jones SM. Advair prescribing patterns in a state Medicaid and child health insurance program. In: American Academy of Allergy, Asthma, and Immunology Annual Meeting. San Diego, California; 2007.
17. FDA News Release. FDA Announces New Safety Controls for Long-Acting Beta Agonists, Medications Used to Treat Asthma. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnoun cements/2010/ucm200931.htm (Accessed November 17, 2014).
18. Lemanske RF Jr., Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol. 2010;126:449-452.
19. Szefler SJ, Busse WW. The longacting beta-adrenergic agonist controversy in asthma: troublesome times!. J Allergy Clin Immunol. 2012; 130:1256-1259.
20. Zhou EH, Kang EM, Seymour S, Iyasu S. Long-acting beta-adrenergic agonist dispensings in pediatric and adolescent asthma patients, 2003- 2011. In: 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Montreal, Canada; 2013.
21. Policy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid/Long-Acting Beta-Agonists. 2012. http://phar macy.oregonstate.edu/drug-policy/ sites/default/fi les/pages/dur-board/ evaluations/articles/2012-05-31-IC S-LABA%20-Pol-Eval.pdf Accessed September 4, 2013.
22. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27: 299-309.
23. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2009; 62:143-148.
24. Karpel JP, Peters JI, Szema AM, et al. Differences in physicians' selfreported knowledge of, attitudes toward, and responses to the black box warning on long-acting betaagonists. Ann Allergy Asthma Immunol. 2009;103:304-310.
25. Ye X, Gutierrez B, Zarotsky V, et al. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr Med Res Opin. 2009;25:2251-2258.
26. Dusetzina SB, Higashi AS, Dorsey ER, et al. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care. 2012; 50:466-478.
27. Olfson M, Marcus SC, Druss BG. EFfects of Food and Drug Administration warnings on antidepressant use in a national sample. Arch Gen Psychiatry. 2008;65:94-01.
28. Valuck RJ, Libby AM, Orton HD, et al. Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry. 2007;164:1198-1205.
29. Medicaid: A Primer - Key Information on the Nation's Health Coverage Program for Low-Income People. The Henry J. Kaiser Family Foundation. http://kff.org/medic aid/issue-brief/medicaid-a-primer/ (Accessed November 17, 2014).
30. Clement LT, Jones CA, Cole J. Health disparities in the United States: childhood asthma. Am J Med Sci. 2008;335:260-265.
31. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. Boston: Houghton Mifflin; 2001.
32. Leal I, Romio SA, Schuemie M, et al. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol. 2013;75:861-868.
33. Thomas K, Schmidt MS. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. New York Times; 2012.
34. Whalen J. Glaxo Tries to Shake Marketing Questions on Advair. WSJ. 2012.
35. Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting innodatabeta agonists for the treatment of asthma: clearing the air. Thorax. 2012;67:342-349.
36. Ducharme FM, Ni Chroinin M. Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010(4): CD005533.
37. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled cortico- steroids for treating asthma. N Engl J Med. 2011;364:2473-2475.